EP1423144A4 - Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease - Google Patents
Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's diseaseInfo
- Publication number
- EP1423144A4 EP1423144A4 EP02753530A EP02753530A EP1423144A4 EP 1423144 A4 EP1423144 A4 EP 1423144A4 EP 02753530 A EP02753530 A EP 02753530A EP 02753530 A EP02753530 A EP 02753530A EP 1423144 A4 EP1423144 A4 EP 1423144A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cd40r
- alzheimer
- disruption
- disease
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31111501P | 2001-08-10 | 2001-08-10 | |
| US311115P | 2001-08-10 | ||
| PCT/US2002/027035 WO2003014328A2 (en) | 1999-06-01 | 2002-08-12 | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1423144A2 EP1423144A2 (en) | 2004-06-02 |
| EP1423144A4 true EP1423144A4 (en) | 2006-08-02 |
Family
ID=32298094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02753530A Withdrawn EP1423144A4 (en) | 2001-08-10 | 2002-08-12 | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1423144A4 (en) |
| AU (1) | AU2002313811A1 (en) |
| CA (1) | CA2467919A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023590A2 (en) * | 1998-10-20 | 2000-04-27 | Georgetown University Medical Center | INHIBITION OF CD40-MEDIATED NFλB ACTIVATION |
| WO2001096397A2 (en) * | 2000-06-09 | 2001-12-20 | Biogen, Inc. | Cd154 variants and uses thereof |
-
2002
- 2002-08-12 EP EP02753530A patent/EP1423144A4/en not_active Withdrawn
- 2002-08-12 CA CA002467919A patent/CA2467919A1/en not_active Abandoned
- 2002-08-12 AU AU2002313811A patent/AU2002313811A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023590A2 (en) * | 1998-10-20 | 2000-04-27 | Georgetown University Medical Center | INHIBITION OF CD40-MEDIATED NFλB ACTIVATION |
| WO2001096397A2 (en) * | 2000-06-09 | 2001-12-20 | Biogen, Inc. | Cd154 variants and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| STUBER ECKHARD ET AL: "Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion", BIOSIS, 1996, XP002189392 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2467919A1 (en) | 2003-02-20 |
| EP1423144A2 (en) | 2004-06-02 |
| AU2002313811A1 (en) | 2003-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003284968A8 (en) | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease | |
| AU2001233299A1 (en) | Methods for treating alzheimer's disease | |
| EP1392287B8 (en) | Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease | |
| EP1416961A4 (en) | Composition and method for the treatment of disease | |
| AU2002306848A1 (en) | Methods of treating alzheimer's disease with piperidin derivates | |
| AU2003206413A8 (en) | Substituted amino carboxamides for the treatment of alzheimer's disease | |
| AU2003220096A8 (en) | Methods for alzheimer's disease treatment and cognitive enhancement | |
| AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
| AU3173301A (en) | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity | |
| AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
| AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
| AU2003209301A8 (en) | Treatments for neurotoxicity in alzheimer's disease | |
| AU3840802A (en) | Methods and compositions for the treatment of diseases of the eye | |
| EP1364648A4 (en) | Cryptotanshinone for preventing and alleviating alzheimer's disease | |
| IL172213A0 (en) | Compounds useful in the therapy of alzheimer's disease and formulations containing them | |
| AU2003248660A8 (en) | Treatment of vascular dysfunction and alzheimer's disease | |
| EP1181550A4 (en) | Methods for the identification of compounds for the treatment of alzheimer's disease | |
| GB0011408D0 (en) | Therapeutic combination for treating Alzheimer's Disease | |
| PL377110A1 (en) | Prevention and treatment of alzheimer's disease | |
| EP1423144A4 (en) | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease | |
| AU2003230848A8 (en) | Methods and compositions for treating alzheimer's disease | |
| AU2003286530A8 (en) | Substituted peptides useful in the treatment of alzheimer's disease | |
| AUPR227000A0 (en) | Agents for the treatment of alzheimer's disease and screening and methods for the same | |
| AU2002324446A1 (en) | Substituted aminoalcohols useful in treatment of alzheimer's disease | |
| AU2002316622A1 (en) | Aminediols for the treatment of alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20040309 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20060705 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/68 20060101ALI20060629BHEP Ipc: G01N 33/50 20060101ALI20060629BHEP Ipc: A61K 39/00 20060101ALI20060629BHEP Ipc: A61K 38/00 20060101AFI20060629BHEP |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ROSKAMP RESEARCH LLC |
|
| 17Q | First examination report despatched |
Effective date: 20080303 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20100302 |